石药集团收到阿斯利康合作项下1000万美元里程碑付款

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

# CSPC PHARMACEUTICAL GROUP LIMITED

## 石 藥 集 團 有 限 公 司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

RECEIPT OF US$10 MILLION MILESTONE PAYMENT UNDER THE STRATEGIC RESEARCH COLLABORATION AGREEMENT WITH ASTRAZENECA

Reference is made to the announcement of CSPC Pharmaceutical Group Limited (the ‘‘Company’’, together with its subsidiaries, the ‘‘Group’’) dated 13 June 2025, in relation to the entering into of a strategic research collaboration agreement (the ‘‘Agreement’’) between the Group and AstraZeneca (the ‘‘Announcement’’) for the discovery and development of novel oral small molecule candidates. Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the Announcement.

As disclosed in the Announcement, the Group agreed to discover pre-clinical candidates (‘‘PCC’’) for multiple targets as selected by AstraZeneca with potential to treat diseases across indications, including a pre-clinical small molecule oral therapy for immunological diseases.

The Board is pleased to announce that the Group has received a milestone payment of US$10 million from AstraZeneca on 5 August 2026 in relation to the exercise of license option for one of the PCC programs under the terms of the Agreement, indicating that the relevant research and development work under the Agreement is progressing steadily as planned.

The development, manufacturing and commercialisation of the relevant licensed products are subject to uncertainties. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company. The Company will make further announcement(s) as and when appropriate to disclose material developments in relation to the Agreement.

By Order of the Board CSPC Pharmaceutical Group Limited CAI Dong Chen Chairman Hong Kong, 5 August 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.